Cooksley, TimGirotra, MonicaGinex, PamelaGordon, Ruth AnnAnderson, RonaldBlidner, Ada GabrielaChoi, JenniferDougan, MichaelGlezerman, IlyaGupta, DiptiJohnson, DouglasShannon, Vickie R.Suarez-Almazor, MariaRapoport, Bernardo Leon2020-10-262020-12Cooksley, T., Girotra, M., Ginex, P. et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities. Support Care Cancer 28, 6175–6181 (2020). https://doi.org/10.1007/s00520-020-05709-1.0941-4355 (print)1433-7339 (online)10.1007/s00520-020-05709-1http://hdl.handle.net/2263/76603Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment, transforming outcomes in melanoma and showing benefit in a range of malignancies. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Immune-mediated endocrinopathies include hypophysitis, thyroiditis, and insulin-dependent diabetes mellitus. These presentations, which may be vague and non-specific, can be life-threatening if not diagnosed and treated appropriately. This review considers the work-up and management of immune-mediated endocrinopathies and also considers the role of advanced practice practitioners in the management of immune-mediated toxicities. These state-of-the-art MASCC recommendations represent a comprehensive overview of the management and clinical work-up in those in whom the diagnosis should be considered.en© Springer-Verlag GmbH Germany, part of Springer Nature 2020. The original publication is available at : http://link.springer.com/journal/520.Immune checkpoint inhibitor (ICI)Advanced practice provider (APP)CorticosteroidsDiabetes mellitusHyperglycemiaHypophysitisThyroiditisPostprint Article